No Data
No Data
J.P. Morgan Maintains ROCHE HOLDINGS AG(RHHVF.US) With Sell Rating, Maintains Target Price $256.08
Genentech's Prasinezumab Phase IIb Study Misses Primary Endpoint But Shows Potential In Early Parkinson's Disease
Deutsche Bank Maintains ROCHE HOLDINGS AG(RHHVF.US) With Sell Rating, Cuts Target Price to $279.88
Jefferies Maintains ROCHE HOLDINGS AG(RHHVF.US) With Hold Rating
Reported Earlier, Roche's Genentech Presents Long-Term Data at ASH 2024 Highlighting Durable Remissions With Fixed-Duration Columvi And Lunsumio
Berenberg Bank Maintains ROCHE HOLDINGS AG(RHHVF.US) With Hold Rating, Raises Target Price to $330.01
No Data